Risk Factors for Severe Hypertension and Proteinuria After Treatment With Vascular Endothelial Growth Factor Signaling Pathway Inhibitors Among Patients With Cancer-Reference-Cited by-同舟云学术

Risk Factors for Severe Hypertension and Proteinuria After Treatment With Vascular Endothelial Growth Factor Signaling Pathway Inhibitors Among Patients With Cancer

Published:2024-06 Issue:6 Volume:9 Page:1897-1902
ISSN:2468-0249
Container-title:Kidney International Reports
language:en
Short-container-title:Kidney International Reports

Author:

Hanna Paul E.,Anumolu Rajesh K.,Motwani Shveta S.,Chen Kevin L.,Katz-Agranov Nurit,Green-Lingren Olivia,Yilmam Osman A.,Jhaveri Kenar D.,Kitchlu Abhijat,Kala Jaya,Sise Meghan E.,Gupta Shruti

Funder

National Institutes of Health

Dana-Farber Cancer Institute

NIDDK

Publisher

Elsevier BV

Reference9 articles.

1. Vascular and metabolic implications of novel targeted cancer therapies: focus on kinase inhibitors;Li;J Am Coll Cardiol,2015

2. Mechanisms of VEGF (vascular endothelial growth factor) inhibitor-associated hypertension and vascular disease;Pandey;Hypertension,2018

3. Increase in blood pressure associated with tyrosine kinase inhibitors targeting vascular endothelial growth factor;Waliany;Cardio Oncol,2019

4. Vascular endothelial growth factor inhibitor-induced hypertension: basics for primary care providers;Escalante;Cardiol Res Pract,2011

5. Established and emerging cancer therapies and cardiovascular system: focus on hypertension-mechanisms and mitigation;Butel-Simoes;Hypertension,2023

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiorenal Impact of Anti-Cancer Agents: The Intersection of Onco-Nephrology and Cardio-Oncology;Cardiorenal Medicine;2024-04-29